Full Press Release Details
odronextamab bla accepted for fda review for the treatment of relapsed refractory follicular lymphoma.
REGN
odronextamab bla accepted for fda review for the treatment of relapsed refractory follicular lymphoma
Key Takeaway: odronextamab bla accepted for fda review for the treatment of relapsed refractory follicular lymphoma